Eli Lilly has entered a collaboration with Seamless Therapeutics worth up to $1.12 billion to co-develop gene editing therapies targeting genetic forms of hearing loss. The agreement grants Lilly exclusive rights to advance candidate therapies developed using Seamless’s recombinase-based platform, which is engineered to perform site-specific DNA edits by inserting or replacing gene fragments. Currently, there are currently no approved pharmacological treatments for reversing genetic hearing loss.
…
